天康生物(002100.SZ)2月生豬銷售收入環比降39.05% 同比升110.2%
格隆匯3月9日丨天康生物(002100.SZ)公佈,公司2020年2月份銷售生豬3.42萬頭,銷量環比下降36.55%,同比下降52.17%;銷售收入1.03億元,銷售收入環比下降39.05%,同比增長110.2%。
2020年1-2月,公司累計銷售生豬8.81萬頭,較去年同期下降35.22%;累計銷售收入2.72億元,較去年同期增長142.86%。
2020年2月,公司生豬銷量和銷售收入環比下降以及銷量同比下降的主要原因是新冠肺炎疫情爆發以來,國家為了防控疫情蔓延,今年2月份實行了限制人員流動的措施,同時零售、餐飲等行業暫停營業,致使豬肉消費大幅度下降所致。
2020年2月公司生豬銷售收入同比增長主要原因是由於國內生豬供給緊張,公司生豬銷售價格較去年同期大幅度上漲所致。
隨着新冠肺炎疫情趨穩,人員流動的放開,零售、餐飲等行業恢復營業,豬肉消費將逐步回升,預計3月份公司生豬銷量將有明顯回升。隨着公司在河南、甘肅地區的母豬開產,預計從二季度開始公司生豬出欄將實現快速上量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.